The Vascular-Dependent and -Independent Actions of Calcitonin Gene-Related Peptide in Cardiovascular Disease

Fulye Argunhan* and Susan D. Brain

Section of Vascular Biology & Inflammation, School of Cardiovascular Medicine & Research, BHF Centre of Excellence, King’s College London, London, United Kingdom

The treatment of hypertension and heart failure remains a major challenge to healthcare providers. Despite therapeutic advances, heart failure affects more than 26 million people worldwide and is increasing in prevalence due to an ageing population. Similarly, despite an improvement in blood pressure management, largely due to pharmacological interventions, hypertension remains a silent killer. This is in part due to its ability to contribute to heart failure. Development of novel therapies will likely be at the forefront of future cardiovascular studies to address these unmet needs. Calcitonin gene-related peptide (CGRP) is a 37 amino acid potent vasodilator with positive-ionotropic and -chronotropic effects. It has been reported to have beneficial effects in hypertensive and heart failure patients. Interestingly, changes in plasma CGRP concentration in patients after myocardial infarction, heart failure, and in some forms of hypertension, also support a role for CGRP on hemodynamic functions. Rodent studies have played an important role thus far in delineating mechanisms involved in CGRP-induced cardioprotection. However, due to the short plasma half-life of CGRP, these well documented beneficial effects have often proven to be acute and transient. Recent development of longer lasting CGRP agonists may therefore offer a practical solution to investigating CGRP further in cardiovascular disease in vivo. Furthermore, pre-clinical murine studies have hinted at the prospect of cardioprotective mechanisms of CGRP which is independent of its hypotensive effect. Here, we discuss past and present evidence of vascular-dependent and -independent processes by which CGRP could protect the vasculature and myocardium against cardiovascular dysfunction.

Keywords: CGRP, cardiovascular, heart, mouse, nitric oxide, hypertension, heart failure

INTRODUCTION

The discovery of Calcitonin gene-related peptide (CGRP) mRNA in the rat hypothalamus by Amara et al. (1982) sparked a series of studies exploring the effect of CGRP in the central and peripheral systems, where it is widely distributed. The authors discovered that human CALCA gene, which codes for the thyroid gland hormone calcitonin, can also produce CGRP via alternative splicing in neural tissues. CGRP is a member of the calcitonin family of peptides, that include adrenomedullin,
adrenomedullin 2/intermedin and amylin (Russell et al., 2014). Soon after, it was found that CGRP has two structurally similar isoforms – the α and β, which are encoded by two distinct genes (Amara et al., 1985). Both isoforms are primarily located in sensory C- and Aδ-fibers (Gibson et al., 1984), and it is generally accepted that despite 94% sequence identity between the two isoforms, β-CGRP synthesis and expression is concentrated around the enteric nervous system, immune cells and pituitary gland (Steenbergh et al., 1985; Brain and Grant, 2004) whereas α-CGRP is primarily involved in the central and peripheral nervous systems, and consequently, is the more extensively studied isoform in cardiovascular studies. This review aims to discuss past and present literature on CGRP in hypertension and heart failure to stimulate thought on the future of CGRP and cardiovascular research, with a particular focus on α-CGRP.

The current consensus is that, upon neuronal depolarization, α- or β-CGRP is released from sensory neurons via calcium-dependent exocytosis to bind to its receptor situated on the plasma membrane of several cell types including, but not limited to, smooth muscle cells (Argunhan et al., 2021), endothelial cells (Gray and Marshall, 1992a) and cardiomyocytes (Clark et al., 2021). The receptor complex is composed of a seven domain G-protein coupled receptor (GPCR) known as calcitonin receptor-like receptor (CRLR) and a single transmembrane protein recognized as receptor activity modifying protein-1 (RAMP1). RAMP1 is required for trafficking of the receptor to the cell surface to form a heterodimer with CRLR and mediate high-affinity binding to CGRP. Upon activation of the CRLR/RAMP1 receptor, G-protein induced signaling cascade is initiated, with Gαs-induced cyclic adenosine monophosphate (cAMP) being the major secondary messenger involved (McLatchie et al., 1998; Pioszak and Hay, 2020). The CGRP family of receptors also comprise two other RAMP proteins; RAMP2 and RAMP3. There is evidence that CGRP may be able to signal via receptors including these components. The receptors involved comprise the calcitonin receptor (CTR) interacting with RAMP1, commonly called the amylín receptor and CRLR interacting with RAMP2, the adrenomedullin receptor (Hay et al., 2018). The selectivity of CGRP for receptors other than CRLR/RAMP1 is under investigation.

Due to the CRLR/RAMP1 receptor complex being expressed in the plasma membrane of smooth muscle cells and endothelial cells, CGRP-induced vasodilation can manifest via two distinct but related mechanisms. The CGRP ligand can bind directly to the receptor complex in vascular smooth muscle cells to induce PKA-mediated smooth muscle relaxation, or it can interact with its receptor complex in endothelial cells to induce endothelial-dependent relaxation via nitric oxide signaling (Crossman et al., 1990; Gray and Marshall, 1992b). In vascular smooth muscle cells, CGRP-induced PKA phosphorylation leads to: reduced intracellular Ca2+ concentration; reduced binding affinity of myosin light chain kinase (MLCK) to Ca2+-calmodulin complex; and activation of ion channels such as ATP-sensitive potassium channels (KATP). All of these contribute to smooth muscle cell relaxation, and thus vasodilation (Brain and Grant, 2004; Figure 1A). In endothelial cells, PKA phosphorylation of eNOS results in NO generation, which is known to diffuse into neighboring vascular smooth muscles and mediate smooth muscle cell relaxation via guanylyl cyclase and protein kinase G (PKG) signaling induction pathways (Russell et al., 2014).

Additionally, there is some evidence for PKC-mediated responses post-CGRP receptor activation (Walker et al., 2010) but the cAMP response is the most established and understood signaling pathway to date. However, it is important to acknowledge the body of in vitro evidence suggesting that the CGRP receptor can couple with other G proteins (Weston et al., 2016). It is also noteworthy that, in addition to its canonical receptor, CGRP has been shown to interact with other receptors from the CGRP family of peptides, albeit with lower affinity (Hay et al., 2018). Recently, the structure and dynamics of the canonical CGRP receptor has been investigated using single-particle cryo-EM (Liang et al., 2018; Josephs et al., 2021), and agonist bias studies have revealed physiological consequences for the CRLR-RAMP1 complex in different cell types (Clark et al., 2021). Thus, this is an area of much interest that is continually evolving, with RAMP proteins being the subject of investigation.

**CALCITONIN GENE-RELATED PEPTIDE AND VASCULAR TONE – SMALL BUT MIGHTY**

Fisher et al. (1983) were the first to demonstrate the hypertensive effects of systemically administered CGRP in rats, whereas Brain et al. (1985, 1986) showed that intradermal injection of CGRP at femtomole doses induces arteriole dilation, thus increasing blood flow locally in animal and human skin. These studies and others indicated that CGRP is a potent vasodilator, leading researchers to further explore its beneficial potential within the cardiovascular system. As a microvascular vasodilator, the potency of CGRP is approximately 10-fold higher than prostaglandins, up to 100 times greater than other well-established vasodilators such as acetylcholine, thus making CGRP the most potent peripheral vasodilator discovered to date (Russell et al., 2014).

Gennari and Fischer (1985) were first to determine the cardiovascular actions of CGRP on hemodynamic parameters in healthy humans. In addition to CGRP’s intrinsic ability to cause vasodilation and consequently hypotension, the authors revealed that CGRP possesses positive chronotropic and inotropic activities. CGRP was reported to increase the force of contractility after receiving β-CGRP infusion for 24 h (12.5 ug/h). *Ex vivo* experiments reinforce these findings, although the mechanism behind the positive inotropic effect is still to be fully elucidated. Franco-Cereceda et al. (1987) were the first to report the effect of CGRP treatment in isolated human auricles, and interestingly, the authors found both α- and β- isoforms of CGRP to be equally potent in affecting positive inotropy.

Similarly, Struthers et al. (1986) infused hCGRP into healthy patients (545 pmol/min), which, as expected, caused a significant...
Argunhan and Brain CGRP in Cardiovascular Disease

FIGURE 1 | Proposed cardioprotective mechanisms of CGRP in the (A) vasculature and (B) myocardium. (A) In the vasculature, CGRP circulating in the blood or released from sensory neurons can bind to its canonical receptor, the CRLR-RAMP1 complex, expressed in the plasma membrane of vascular smooth muscle and endothelial cells to initiate $G_\alpha_s$-protein signal transduction and subsequently cause relaxation of smooth muscle cells via nitric oxide (NO)-dependent and -independent mechanisms thus leading to vasodilation. (B) In cardiac tissues, there is evidence for CGRP-stimulated modulation of sympathetic outflow and expression of the CRLR-RAMP1 complex on cardiomyocytes. Hence, CGRP has the potential to induce $G_\alpha_s$-protein signaling from sensory and sympathetic nerves leading to increased cardiac contractility, thus positive inotropy and chronotropy. AC, adenyl cyclase; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; GTP, guanosine triphosphate; $K_{ATP}$, ATP-sensitive potassium channels; LTCC, L-type calcium channel; NO, nitric oxide; P, phosphate; PKA, protein kinase A; RyR, ryanodine receptor; sGC, soluble guanylate cyclase. [Images were obtained from smart.servier.com under a Creative Commons Attribution 3.0 Unported License].

decrease in diastolic pressure accompanied with an increase in heart rate. The authors suggested a potential role for CGRP in modulating vascular tone in humans, and this was supported by findings from Girgis et al. (1985) demonstrating that CGRP concentration is fivefold higher than calcitonin. Given that it is widely expressed in the human body, these results raised
the possibility that CGRP is a critical physiological regulator of vascular tone and hemodynamics.

Collectively, these studies laid the foundation for elucidating the biological actions of CGRP, which recently reached fruition in the field of migraine research where CGRP blockers are now used therapeutically (Edvinsson et al., 2018; Kee et al., 2018). Generally, the use of migraine blockers have not been associated with significant cardiovascular effects, indicating that CGRP does not play a major role in cardiovascular regulation in individuals with normal blood pressure (Bigal et al., 2015). Separately, there has been increasing research into elucidating the role of CGRP and of exogenous CGRP, in the cardiovascular system. However, the potential biological importance and underlying mechanisms, particularly with respect to heart failure, will be discussed in later sections.

**CALCITONIN GENE-RELATED PEPTIDE IN HYPERTENSION – VASCULAR-DEPENDENT EFFECTS**

Shekhar et al. (1991) was one of the first to demonstrate the cardiovascular effects of prolonged CGRP infusion (8 ng/kg/min for 8 h) in CHF patients. In agreement with others, they reported significant decreases in cardiac and arterial pressures, as well as in pulmonary and systemic vascular resistance, and increases in cardiac output and stroke volume. Accordingly, the reported hemodynamic changes were absent 30 min after discontinuation of CGRP infusion, consistent with the short half-life of CGRP (approximately 7–30 min) (Kraenzlin et al., 1985).

Concomitantly, preclinical data from rodents have facilitated human studies. Research in the 1990s focusing on the role of CGRP in blood pressure control was dominated by preclinical hypertension studies carried out in rats that were spontaneously hypertensive (SHR), treated with hypertensive agents, or hypertensive due to surgical intervention. These studies and others reported in vivo evidence that CGRP can protect against hypertension and the vasoconstrictor effects of hypotensive agents including angiotensin-II (AngII) (Itabashi et al., 1988; Fujikawa et al., 1991), deoxycorticosterone-salt (Fujikawa et al., 1991), noradrenaline (Fujikawa et al., 1991), doxycorticosterone-salt (Supowit et al., 1997; Supowit et al., 2005), and the nitric oxide synthase (NOS) inhibitor L-NAME (Gardiner et al., 1991; Gangula et al., 1997), making progress toward understanding the mechanism of action of CGRP (Kumar et al., 2019a). Kawasaki et al. (1990) found that reduced CGRP-containing nerves in SHRs contribute to the development and maintenance of hypertension, further supporting a protective role for CGRP in hypertension. Furthermore, ex vivo experiments, particularly in isolated arterial and mesenteric resistance vessels, have complemented the in vivo data to-date (Nelson et al., 1990; Kawasaki et al., 1998; Kawasaki et al., 1999).

It has been difficult to study α-CGRP in vivo due to its peptide nature, therefore the use of genetically engineered mice has been fitting. Genetic deletion of CGRP has been reported to cause elevated baseline blood pressure in some (Gangula et al., 2000; Oh-hashi et al., 2001; Li et al., 2004; Mai et al., 2014) but not all studies (Smillie et al., 2014; Argunhan et al., 2021). This is likely due to differences in methodology, such as differences in the precise genetic deletion site when generating knockout (KO) mouse lines, particular strains preserving unique hemodynamic phenotypes, and the utilization of various different blood pressure measurement techniques. Most importantly, most preclinical hypertension studies conclude that genetic deletion of CGRP is detrimental, if not in a naïve state, then evidently in a stressed or hypertensive setting. This indicates that endogenous CGRP may only be functionally active in cardiovascular dysfunction. CGRP blockers (antibodies and now CGRP receptor antagonists) have been studied in humans with migraine over several years now (Al-Hassany and Van Den Brink, 2020). The majority of findings from recent clinical trials report little or no change in blood pressure from migraine patients who received anti-CGRP therapy. Additionally, very few cardiovascular side-effects have been observed in migraine patients taking CGRP blockers (Tepper, 2019). Thus, it is not yet known whether CGRP has a functionally important cardiovascular role in humans, apart from the neurogenic vasodilator response observed typically in patients with migraine (Tepper, 2019). However, due to CGRP being widely expressed and the increasing evidence for a cardioprotective role, there are concerns regarding long-term blockade of CGRP in migraine patients who may also suffer from cardiovascular complications (Rubio-Beltran and Maassen van den Brink, 2019). The observation of cardiovascular adverse effects with CGRP blockers in migraine has not been commonly observed. However, a recent study conducted a retrospective analysis of cases reporting a CGRP receptor antagonist (erenumab) associated with elevated blood pressure (BP) (Saely et al., 2021). The authors identified 61 cases of elevated BP between May 2018 and April 2020, of which the median systolic BP increase was 39 mm Hg. Interestingly, 44% of reported cases required anti-hypertensive medication and the elevated BP occurred most frequently within a week of commencing erenumab treatment. Most importantly, the prescribing information for erenumab/Aimovig now includes hypertension. This further supports the need to continue monitoring cardiovascular parameters in those receiving anti-CGRP therapy for migraine, in addition to continuing research within the CGRP and cardiovascular field (Saely et al., 2021).

Much like CGRP KO mice, RAMP1 KO mice develop high blood pressure (Tsujikawa et al., 2007) and knock-in or overexpression of human RAMP1 in all (Sabharwal et al., 2010) or solely neural tissues (Sabharwal et al., 2019) potentiates CGRP-dependent blood pressure reduction in AngII-induced hypertension. Additionally, in the periphery, in tissues such as skin, it is clear that CGRP is a potent vasodilator and is well placed to play a regulatory role, for example in the recovery of blood flow in the cold-induced vascular response (Aubdool et al., 2014), a response that diminishes as aging occurs (Thapa et al., 2021).

Our research group has reported that, despite a lack of vascular tone modulation at baseline, α-CGRP-specific KO mice display elevated blood pressure after AngII or L-NAME treatment (Smillie et al., 2014; Argunhan et al., 2021). α-CGRP KO mice present with hypertrophic vascular remodeling in their aortic tissues and increased mRNA levels of inflammatory and oxidative...
The protective effects of CGRP discussed thus far are detailed and mostly consistent between research groups, they do not constitute a complete record of documented studies demonstrating a cardioprotective role of CGRP. It is apparent that the beneficial effects of CGRP have been limited due to its short peptide half-life. Our group was fortunate to investigate the therapeutic potential of a longer lasting CGRP agonist in AngII-induced hypertension and mice that underwent abdominal aortic constriction surgery, which eventually caused heart failure via increased pressure-overload on the heart (Aubdool et al., 2017). The acylated α-CGRP analog had been characterized by Nilsson et al. (2016) and has a half-life of >7 h in rodents. Our group demonstrated that daily administration of the CGRP analog [50 nmol/kg/day, subcutaneous injection (s.c.)] for 2 weeks in AngII-treated mice led to significant attenuation of AngII-induced hypertension and protected against vascular, renal and cardiac dysfunction. α-CGRP analog-treated mice presented with attenuated hypertrophic and fibrotic markers as well as reduced inflammation and oxidative stress. Furthermore, the α-CGRP analog was effective in preserving ejection fraction, a measure of cardiac function, and protecting against fibrosis and apoptosis in cardiac tissues of mice that had undergone abdominal aortic constriction surgery and consequently developed heart failure. Moreover, α-CGRP-treated mice presented with better vascularization in their hearts and expressed reduced mRNA and protein expression of biomarkers for hypertrophy, apoptosis, oxidative stress and inflammation. These findings agree with other in vivo heart failure studies (Li et al., 2013; Kumar et al., 2019b; Kumar et al., 2020). In vitro experiments have demonstrated similar findings in different cell types. CGRP administration has been shown to: stimulate proliferation of endothelial cells (Haegerstrand et al., 1990), supporting CGRP’s proangiogenic effects in vivo; reduce vascular smooth muscle cell proliferation (Li et al., 1997) and thus vascular hypertrophy; and show antioxidant and antiapoptotic effects in dorsal root ganglion (DRG) neurons (Liu et al., 2019).

However, data from the Aubdool et al. (2017) study suggests these protective effects of CGRP can be long lasting using a novel α-CGRP agonist with an extended half-life. The CGRP agonist can delay the onset and development of hypertension through cardioprotective mechanisms in addition to ameliorating pressure overload-induced heart failure. Interestingly, mice with heart failure that had received the α-CGRP analog or its vehicle presented with comparable blood pressures, indicating that the cardioprotective mechanisms involved are likely to be blood pressure-independent. Furthermore, the same analog has recently been administered to rats that have undergone permanent occlusion of their left coronary artery to investigate coronary perfusion in myocardial infarction. Three injections of the CGRP analog, SAX, at 20 min, 24 and 48 h after coronary ligation, was sufficient to improve myocardial perfusion recovery in rats, indicative of myocardium protection after ischemic damage (Bentsen et al., 2021). An earlier study by Kallner et al. (1998) reported CGRP-mediated improvement in post-ischemic coronary flow early after MI, but whether treatment with the long lasting agonist will increase cardioprotective effects in the long term is still to be investigated.

LONG-LASTING AGONIST OF CALCITONIN GENE-RELATED PEPTIDE

While the protective effects of CGRP discussed thus far are detailed and mostly consistent between research groups, they
CALCITONIN GENE-RELATED PEPTIDE
IN THE MYOCARDIUM –
VASCULAR-INDEPENDENT EFFECTS

The heart is densely innervated by nerve fibers comprised of: the sympathetic trunk, which starts from the base of the skull; parasympathetic nerves, including the right and left vagus nerves; cervical cardiac nerves, which run parallel to the vagus nerves; and the cardiac plexus at the base of the heart. α-CGRP producing sensory nerves have been reported within the perivascular layer of coronary arteries, in the myocardium of ventricles, and within the cardiac conduction system (Gulbenkian et al., 1993). In addition to this, CGRP immunoreactivity has been associated with: myocytes from atria, coronary vessels, local parasympathetic ganglia and with epi-and endocardia (Franco-Cereceda et al., 1987). Therefore, it is likely that CGRP signaling manifests within cardiac cells, in addition to cardiac vessels, and that the sensory, parasympathetic and sympathetic nerves are involved in facilitating CGRP-induced signaling within, and surrounding, the myocardium.

Several in vivo studies of hypertension and heart failure have reported an upregulation of RAMP1 and/or CGRP expression in pathological conditions (Supowit et al., 1995; Li and Wang, 2005; Aubdool et al., 2017; Argunhan et al., 2021). In addition to this, Franco-Cereceda and Liska (2000) have previously reported the presence of a subpopulation of capsaicin-sensitive cardiac C-fiber afferents that store CGRP, substance P and neurokinin A. The C-fibers are likely to express transient receptor potential vanilloid 1 (TRPV1) channel, which upon stimulation by capsaicin lead to CGRP release (Franco-Cereceda, 1991). This finding of local efferent release of CGRP in the heart is consistent with the presence of capsaicin-sensitive receptors on the epicardial surface of rat hearts (Zahner et al., 2003). More recently, Moreira et al. (2020) reported elevated CGRP levels in human atrial tissue lysates and atrial cardiomyocytes obtained from patients with atrial fibrillation, in agreement with Franco-Cereceda et al. (1987) who found between threefold and fourfold higher levels of CGRP-like immunoreactivity in atria compared to ventricles. These studies describe and support a structural basis for CGRP signaling within cardiac tissues.

Furthermore, coinciding with its interactions in vascular smooth muscle and endothelial cells, CGRP has similarly been demonstrated to bind to its canonical receptor complex and activate Ga_i-signaling in cardiomyocytes (Huang et al., 1999; Sueur et al., 2005; Schavinski et al., 2021). It is well established that an increase in cAMP concentration followed by PKA activation leads to phosphorylation of key Ca^{2+}-handling proteins including phospholamban, ryanodine receptor, voltage-gated L-type Ca^{2+} channels, troponin I, and myosin binding protein C; all which play an essential role in cardiac excitability and contraction (Zaccolo, 2009). Earlier studies have reported that activation of the CRLR/RAMP1 complex leads to stimulation of a contractile response in adult rat ventricular cardiomyocytes (Bell and McDermott, 1994; Bell et al., 1995). However, unlike the vascular-dependent effects of CGRP, the precise mechanism of action of CGRP in cardiomyocytes remains to be fully elucidated.

Interestingly, a recent study investigating GPCR agonist bias in CGRP and CGRP-like family peptides demonstrated that, in human ventricular cardiomyocytes, CGRP is more potent than adrenomedullin and adrenomedullin 2/intermedin in generating cAMP (Clark et al., 2021). Acute cAMP elevation is known to compensate for impaired cardiac function by modulating the positive-inotropic, -chronotropic and -lusitropic responses in the heart. Thus, in addition to its vascular dependent actions, it is tempting to speculate that CGRP-induced positive-inotropy and -chronotropy observed in earlier human studies could be a consequence of vascular-independent actions via direct interaction with cardiomyocytes. Chronic cAMP activation, however, has been associated with adverse cardiac remodeling (Triposkiadis et al., 2009). Importantly, cAMP is a pleiotropic secondary messenger and thus able to produce several biological outcomes in response to different stimuli. Moreover, locally accumulated cAMP has been shown to ameliorate cardiac hypertrophy via cAMP-degrading enzyme phosphodiesterase-2 (PDE2; Zoccarato et al., 2015). The regulation and function of local cAMP-PKA signaling remains to be fully understood, and compartmentalized cAMP-PKA has been suggested to play a key role in cardiac physiology and pathophysiology (Surdo et al., 2017).

Coupling of the CRLR-RAMP1 complex to Ga_i can lead to other responses such as phosphorylation of ERK1/2 or cell proliferation; a response which has been suggested to be cell type dependent (Clark et al., 2021). Interestingly, the CGRP family of receptors, including CRLR/RAMP1, can couple to Ga_i and Ga_q subunits too, although there is little evidence of this in cardiomyocytes (Nishikimi et al., 1998; Walker et al., 2010). These findings further support the need to investigate CGRP-signaling in cardiomyocytes and fibroblasts in vitro, which may help to clarify the mechanism of action behind the cardioprotective effects of CGRP reported in whole body physiology studies (Li et al., 2013; Aubdool et al., 2017; Kumar et al., 2019b; Skaria et al., 2019; Kumar et al., 2020; Argunhan et al., 2021), especially in studies that have shown blood pressure independent effects of CGRP (Aubdool et al., 2017; Skaria et al., 2019).

In addition to its direct effect on cardiomyocytes, CGRP has also been shown to modulate sympathetic nervous activity (Figure 1B). Activation of β-adrenoceptors via increased sympathetic nervous activity leads to Ga_s-signaling-induced cardiac contractility. Earlier studies suggest that CGRP-induced positive inotropic effects may be, at least partially, due to increased sympathetic activity (Fisher et al., 1983; Gennari and Fischer, 1985; Struthers et al., 1986; Katori et al., 2005). On the other hand, Kawasaki (2002) reported that exogenous CGRP treatment can impair noradrenergic-induced constriction in rat mesenteric vessels. Thus, it is thought the activation of increased sympathetic activity reported in some studies is part of a compensatory reflex system to combat CGRP-induced hypotension. Considering that exogenous administration of CGRP primarily lowers blood pressure, its ability to stimulate the sympathetic nervous system is likely to be minimal and secondary to its primary action of inducing vasodilation. Evidence suggests that stimulation of the sympathetic nervous system may be one of the mechanisms CGRP is able to stimulate in situations where inotropic support is necessary (Figure 1B).
It is unclear whether the aforementioned inotropic effects of CGRP are solely a consequence CGRP directly binding to its receptor complex found on myocardial cells (Bell and McDermott, 1994), modulation of the sympathetic nervous system, or an as yet unknown mechanism. A combination of these pathways is likely, with the choice dependent on the pathophysiological setting. It is important to acknowledge that selective and non-selective β-blockers, which target β-adrenoceptors, constitute well-established therapeutics for cardiovascular diseases such as hypertension, coronary artery disease and severe tachycardia. They decrease contractility, thus reducing cardiac output and oxygen demand (Chatterjee et al., 2013; McDonagh et al., 2021), and are therefore part of the evidence-based long-term management of heart failure with reduced ejection fraction (HFrEF). β-blockers are, however, concurrently used with ACE inhibitors, and in many cases, an aldosterone inhibitor or diuretic, to off-set other symptoms of heart failure. Despite being generally well tolerated and recommended as pharmacological therapeutics for heart failure patients who require long-term management of their medical symptoms, there remains an unmet therapeutic need for better management of HF pathophysiology.

Contrary to the above, increasing inotropy can also be of benefit in heart failure patients (Page et al., 2016). However, this is specifically for those who require inotropic- or short-term hemodynamic support due to suffering with decompensated HFrEF, presenting with low cardiac output and hypotension or evidence of end-organ hypoperfusion (McDonagh et al., 2021). Sympathetic cardiac stimulants such as dopamine and dobutamine are therefore still recommended for use in such cases (Bistola et al., 2019) and vasodilator therapeutics are also first-line agents for acute HF with elevated blood pressure (McDonagh et al., 2021). Human studies suggest that CGRP administration is protective in patients who require short-term inotropic support, whilst long-term pre-clinical studies indicate CGRP can improve cardiovascular function parameters in pressure-overload-induced heart failure.

However, whether a sub-pressor dose of CGRP can protect against the development and progression of hypertension and heart failure needs to be investigated further. If CGRP can indeed protect against cardiovascular disease without lowering blood pressure, this answers one query but raises further questions regarding its mechanism of action. Vasodilators are known to primarily reduce total peripheral resistance via vasodilation in blood vessels, thus lowering blood pressure. This in turn acutely enhances sympathetic stimulation due to the baroreceptor reflex, hence increasing heart rate and cardiac contractility (positive-chronotropy and -inotropy) in the short-term. The dilation of venous and arterial vessels also leads to a reduction in venous return to the heart (pre-load), which reduces congestion and after-load, therefore increasing stroke volume, cardiac output and subsequent relief of symptoms. It is for these reasons that vasodilators such as nitrates or nitroprusside are recommended for management of acute heart failure (AHF) in patients with elevated blood pressure (McDonagh et al., 2021). If a dilator such as CGRP does not affect blood pressure but is able to improve cardiac function, this adds complexity to our understanding of how vasodilators can modulate cardiac function. The recent data from Aubdool et al. (2017) and Skaria et al. (2019) suggests that CGRP can regulate cardiac function independently of blood pressure, thus via vascular-dependent and -independent pathways.

Collectively, these studies propose vascular-independent mechanisms for CGRP in cardiac tissues and may be the primary mechanism by which CGRP elicits protection in the absence of vascular tone changes. There is evidence supporting that CGRP can act locally on cardiomyocytes to elicit some of its cardioprotective actions, and future studies should aim to clarify the precise mechanism(s) involved in cardiac pathophysiology.

**DISCUSSION**

A wide spectrum of in vitro, ex vivo, in vivo and human studies have highlighted the therapeutic potential of CGRP in various pathophysiological conditions within the cardiovascular system. Genetic tools such as transgenic mouse lines combined with pharmacological agents including CGRP peptide administration systems and delivery of selective receptor antagonists, means that researchers are well-equipped to investigate the effects of reduced, enhanced and lack of CGRP signaling in whole body pathophysiology studies. More recently, anti-CGRP therapies for treatment of migraine have proven to be successful with generally minimal adverse effects reported. Additional follow-up clinical trials will be welcomed by all to clarify whether long-term CGRP blockade leads to hypertension-related side effects. Meanwhile, long lasting agonists have emerged as a promising avenue for CGRP-therapy in cardiovascular disease, which will facilitate research into the intrinsic proliferative and angiogenic characteristics of CGRP, in addition to its anti-inflammatory and anti-apoptotic effects reported in vivo. Future studies should aim to investigate the blood pressure-independent cardioprotective mechanisms of CGRP treatment in PO-induced heart failure, and whether treatment with the long-lasting agonist could improve outcome after ischemic heart failure. Collectively, these findings further demonstrate the importance of continuing CGRP research to fully elucidate the physiological influence of CGRP in the cardiovascular system, as well as in migraine pathophysiology.

**AUTHOR CONTRIBUTIONS**

FA wrote the first draft. Both FA and SDB finalised the manuscript. Both authors contributed to the article and approved the submitted version.

**FUNDING**

This work was funded by the British Heart Foundation PG/19/14/34268. We apologize to our colleagues whose work could not be cited due to space restraints.
REFERENCES

Al-Hassany, L., and Van Den Brink, A. M. (2020). Targeting CGRP in migraine: a matter of choice and dose. Lancet Neurol. 19, 712–713. doi: 10.1016/S1474-4422(20)30282-9

Amara, S. G., Arriza, J. L., Leff, S. E., Swanson, L. W., Evans, R. M., and Rosenfeld, M. G. (1985). Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 229, 1094–1097. doi: 10.1126/science.2994212

Amara, S. G., Jonas, V., Rosenfeld, M. G., Engel, S. E., and Evans, R. M. (1982). Calcitonin gene-related peptide stimulates adenylate cyclase and guanylate cyclase and relaxes rat thoracic aorta by releasing nitric oxide. Physiol. Rev. 72, 293–312. doi: 10.1152/physrev.1992.72.2.293

Amara, S. G., Arriza, J. L., Leff, S. E., Swanson, L. W., Evans, R. M., and Rosenfeld, M. G. (1985). Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 229, 1094–1097. doi: 10.1126/science.2994212

Amara, S. G., Jonas, V., Rosenfeld, M. G., Engel, S. E., and Evans, R. M. (1982). Calcitonin gene-related peptide stimulates adenylate cyclase and guanylate cyclase and relaxes rat thoracic aorta by releasing nitric oxide. Physiol. Rev. 72, 293–312. doi: 10.1152/physrev.1992.72.2.293
McDonagh, T. A., Metra, M., Adamo, G., Gardner, R. S., Baumbach, A., Bohm, M., et al. (2021). 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Europ. Heart J.* 42, 3599–3726.

Mclatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., et al. (1998). RAMPS regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393, 333–339. doi: 10.1038/30666

Moreira, L. M., Takawale, A., Hulsurkar, M., Menassa, D. A., Antanaviciute, A., Lahiri, S. K., et al. (2020). Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia. *Nature* 587, 460–465. doi: 10.1038/s41586-020-2890-8

Nelson, M. T., Huang, Y., Brayden, J. E., Hescherl, J., and Standen, N. B. (1990). Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels. *Nature* 344, 770–773. doi: 10.1038/344770a0

Nilsen, C., Hansen, T. K., Rosenquist, C., Hartmann, B., Kodra, J. T., Lau, J. F., et al. (2016). Long-acting analogue of the calcitonin gene-related peptide induces positive metabolic effects and secretion of the glucagon-like peptide-1. *Europ. J. Pharmacol.* 773, 24–31. doi: 10.1016/j.ejphar.2016.01.003

Nishikimi, T., Horio, T., Yoshihara, F., Nagaya, N., Matsuo, H., and Kangawa, K. (1998). Effect of adrenomedullin on CAMP and cGMP levels in rat cardiac myocytes and nonmyocytes. *Europ. J. Pharmacol.* 353, 337–344. doi: 10.1016/s0014-2999(98)00400-2

Oh-hashi, Y., Shindo, T., Kurihara, Y., Imai, T., Wang, Y., Morita, H., et al. (2001). Elevated sympathetic nervous activity in mice deficient in alphacGRP. *Circ. Res.* 89, 983–990. doi: 10.1161/01.res.67.7.733

Page, R. L., Li, O’bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., et al. (2016). Drugs that may cause or exacerbate heart failure: a scientific statement from the american heart association. *Circulation* 134, e32–e69.

Pioszaak, A. A., and Hay, D. L. (2020). RAMPS as allostERIC modulators of the calcitonin and calcitonin-like class B G-protein-coupled receptors. *Adv. Pharmacol.* 88, 115–140. doi: 10.1016/bs.apha.2020.01.001

Rubio-Beltran, E., and Maassen van den Brink, A. (2019). Understanding CGRP and cardiovascular risk. *Handb. Exp. Pharmacol.* 255, 131–140. doi: 10.1007/164_2019_204

Russell, F. A., King, R., Smillie, S. J., Kodji, X., and Brain, S. D. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. *Physiol. Rev.* 94, 1099–1142. doi: 10.1152/physrev.00034.2013

Sabharwal, R., Mason, B. N., Kuburas, A., Abboud, F. M., Russo, A. F., and Chapleau, M. W. (2019). Increased receptor activity-modifying protein 1 in the nervous system is sufficient to protect against autonomic dysregulation and hypertension. *J. Cereb. Blood Flow Metab.* 39, 690–703. doi: 10.1177/0271678x17751352

Sabharwal, R., Zhang, Z., Lu, Y., Abboud, F. M., Russo, A. F., and Chapleau, M. W. (2010). Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates Angiotensin-induced hypertension. *Hypertension* 55, 627–635. doi: 10.1161/HYPERTENSIONAHA.109.148171

Saely, S., Croteau, D., Jawidzik, L., Brinker, A., and Kortepeter, C. (2021). Hypertension: A new safety risk for patients treated with erenumab. *Headache* 61, 202–208. doi: 10.1111/head.14051

Schavinski, A. Z., Machado, J., Morgan, H. J. N., Latherback, N., Paula-Gomes, S., Kettellhu, I. C., et al. (2021). Calcitonin gene-related peptide exerts inhibitory effects on autophagy in the heart of mice. *Peptides* 146,170677. doi: 10.1016/j.peptides.2021.170677

Shekhar, Y. C., Anand, I. S., Sarma, R., Ferrari, R., Wahi, P. L., and Poole-Wilson, P. A. (1991). Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. *Am. J. Cardiol.* 67, 732–736. doi: 10.1016/0002-0409(89)90391-8

Smillie, S. J., King, R., Kodji, X., Outzen, E., Potts, G., Fernandes, E., et al. (2014). An ongoing role of alpha-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. *Hypertension* 63, 1056–1062. doi: 10.1161/HYPERTENSIONAHA.113.02517
Argunhan and Brain CGRP in Cardiovascular Disease

Steenbergh, P. H., Hoppener, J. W., Zandberg, J., Lips, C. J., and Jansz, H. S. (1985). A second human calcitonin/CGRP gene. FEBS Lett. 183, 403–407.

Struthers, A. D., Brown, M. J., Macdonald, D. W., Beacham, J. L., Stevenson, J. C., Morris, H. R., et al. (1986). Human calcitonin gene related peptide: a potent endogenous vasodilator in man. Clin. Sci. (Lond) 70, 389–393. doi: 10.1042/cs0700389

Sueur, S., Pesant, M., Rochette, L., and Connat, J. L. (2005). Antiapoptotic effect of calcitonin gene-related peptide on oxidative stress-induced injury in H9c2 cardiomyocytes via the Ramp1/Crlr complex. J. Mol. Cell Cardiol. 39, 955–963. doi: 10.1016/j.yjmcc.2005.09.008

Supowit, S. C., Rao, A., Bowers, M. C., Zhao, H., Fink, G., Steficek, B., et al. (2005). Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. Hypertension 45, 109–114. doi: 10.1161/01.HYP.0000151130.34874.f4

Supowit, S. C., Zhao, H., Hallman, D. M., and Dipette, D. J. (1997). Calcitonin gene-related peptide is a depressor of deoxycorticosterone-salt hypertension in the rat. Hypertension 29, 945–950. doi: 10.1161/01.hyp.29.4.945

Supowit, S. C., Zhao, H., Wang, D. H., and Dipette, D. J. (1995). Regulation of neuronal calcitonin gene-related peptide expression. Role of increased blood pressure. Hypertension 26, 1177–1180. doi: 10.1161/01.hyp.26.6.1177

Surdo, N. C., Berrera, M., Koschinski, A., Brescia, M., Machado, M. R., Carr, C., et al. (2017). FRET biosensor uncovers camp nano-domains at beta-adrenergic targets that dictate precise tuning of cardiac contractility. Nat. Commun. 8:15031. doi: 10.1038/ncomms15031

Tepper, S. J. (2019). Cgrp and headache: a brief review. Neurol. Sci. 40, 99–105. doi: 10.1007/s10072-019-03769-8

Thapa, D., Valente, J. S., Barrett, B., Smith, M. J., Argunhan, F., Lee, S. Y., et al. (2021). Dysfunctional Trpm8 signalling in the vascular response to environmental cold in ageing. eLife 10:e70153. doi: 10.7554/elife.70153

Triposkiadis, F., Karayannis, G., Giannouzis, G., Skolarigis, J., Louridas, G., and Butler, J. (2009). The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol. 54, 1747–1762. doi: 10.1016/j.jacc.2009.05.015

Tsukijawa, K., Yayama, K., Hayashi, T., Matsushita, H., Yamaguchi, T., Shigeno, T., et al. (2007). Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 104, 16702–16707. doi: 10.1073/pnas.0705974104

Walker, C. S., Conner, A. C., Poyner, D. R., and Hay, D. L. (2010). Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol. Sci. 31, 476–483. doi: 10.1016/j.tips.2010.08.006

Weston, C., Winfield, I., Harris, M., Hodgson, R., Shah, A., Dowell, S. J., et al. (2016). Receptor activity-modifying protein-directed G protein signaling specificity for the calcitonin gene-related peptide family of receptors. J. Biol. Chem. 291, 21925–21944.

Zacco, M. (2009). cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br. J. Pharmacol. 158, 50–60. doi: 10.1111/j.1476-5381.2009.00185.x

Zahner, M. R., Li, D. P., Chen, S. R., and Pan, H. L. (2003). Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J. Physiol. 551, 515–523. doi: 10.1113/jphysiol.2003.048207

Zoccarato, A., Surdo, N. C., Aronsen, J. M., Fields, L. A., Mancuso, L., Dodoni, G., et al. (2015). Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2. Circ. Res. 117, 707–719. doi: 10.1161/CIRCRESAHA.114.305892

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Argunhan and Brain. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.